Figures & data
Figure 1. Immunogenic tumor-derived IL-17D recruits NK cells to activate antitumor immunity and promote tumor regression. Secreted from immunogenic tumor cells, IL-17D stimulates the production of MCP-1 from tumor endothelial cells. In turn, MCP-1 attracts monocytes and NK cells into IL-17D-expressing tumors, leading to tumor rejection. Abbreviations: Interleukin-17D (IL-17D); Monocyte Chemotactic Protein 1 (MCP-1, aka CCL2).
![Figure 1. Immunogenic tumor-derived IL-17D recruits NK cells to activate antitumor immunity and promote tumor regression. Secreted from immunogenic tumor cells, IL-17D stimulates the production of MCP-1 from tumor endothelial cells. In turn, MCP-1 attracts monocytes and NK cells into IL-17D-expressing tumors, leading to tumor rejection. Abbreviations: Interleukin-17D (IL-17D); Monocyte Chemotactic Protein 1 (MCP-1, aka CCL2).](/cms/asset/4d8db672-78cd-4b5e-9cc1-7467dc6d84f6/koni_a_954853_f0001_oc.jpg)